A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

This trial is testing JNJ-79635322 — a new targeted drug — in combination with existing multiple myeloma treatments (daratumumab with or without lenalidomide, or pomalidomide) across different patient groups: newly diagnosed myeloma, earlier relapse, or more heavily pre-treated patients. **You may be eligible if...** - You have been diagnosed with multiple myeloma according to standard criteria - Depending on your treatment group: - Treatment A: You have received 1-3 prior treatment lines including a proteasome inhibitor and an immunomodulatory drug (IMiD), OR you are newly diagnosed with myeloma - Treatment B: You have received at least 1 prior line including a proteasome inhibitor and lenalidomide - Your disease is active and requires treatment **You may NOT be eligible if...** - You have had certain prior therapies that conflict with the study regimen - You have significant kidney, liver, or heart problems that make you ineligible - You have an active infection or uncontrolled health condition - You have had prior severe allergic reactions to the study drugs Talk to your doctor to see if this trial is right for you.